脂質調節劑市場－全球產業規模、佔有率、趨勢、機會和預測（按類型、地區和競爭細分，2020-2030 年）

2024 年全球脂質調節劑市場價值為 72.1 億美元，預計到 2030 年將達到 98.4 億美元，預測期內複合年成長率為 5.32%。由於全球心血管疾病和糖尿病發病率上升、人口老化以及膽固醇管理意識增強，市場正在穩步成長。技術創新，特別是神經和治療領域的進步，以及政府和私營部門投資的增加，正在為市場擴張創造有利條件。由於老年人更容易患慢性疾病，對控制血脂異常和預防併發症至關重要的脂質調節劑的需求預計會增加，從而加強了它們在預防心血管護理中的重要性。

關鍵市場促進因素

心血管疾病盛行率上升

主要市場挑戰

開發成本高

主要市場趨勢

生物製藥的崛起

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球脂質調節劑市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型{他汀類藥物（品牌他汀類藥物、他汀類藥物組合和通用他汀類藥物）和非他汀類藥物（纖維酸衍生物、膽汁酸螯合劑、菸鹼酸衍生物和其他新產品）}
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美脂質調節劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲脂質調節劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太地區脂質調節劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲脂質調節劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲脂質調節劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購

第 13 章：全球脂質調節劑市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代治療類型的威脅

第 15 章：競爭格局

• AbbVie Inc
• Amgen Inc.
• Andrx Corp
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Dr. Reddy's Laboratories Ltd.

第 16 章：策略建議

第17章調查會社について,免責事項

The Global Lipid Regulators Market was valued at USD 7.21 billion in 2024 and is projected to reach USD 9.84 billion by 2030, growing at a CAGR of 5.32% during the forecast period. The market is experiencing steady growth driven by a rising global incidence of cardiovascular diseases and diabetes, an aging population, and increasing awareness of cholesterol management. Technological innovations, particularly in neural and therapeutic advancements, as well as increased government and private sector investments, are creating favorable conditions for market expansion. With the elderly being more vulnerable to chronic illnesses, the demand for lipid regulators-essential in managing dyslipidemia and preventing complications-is anticipated to increase, reinforcing their importance in preventive cardiovascular care.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases

The global surge in cardiovascular diseases (CVDs) serves as a key catalyst for the lipid regulators market. CVDs, including coronary artery disease, stroke, and hypertension, are a leading cause of death globally. According to the World Health Organization, CVDs account for nearly 32% of all deaths worldwide. Dyslipidemia, characterized by abnormal cholesterol or triglyceride levels, is a primary risk factor in the development of CVDs. Lipid regulators, particularly statins and other lipid-lowering agents, are vital in controlling cholesterol levels, reducing disease progression, and improving patient outcomes. With a growing global focus on preventive healthcare, the demand for lipid-regulating therapies continues to rise, offering growth opportunities for pharmaceutical companies and healthcare providers.

Key Market Challenges

High Development Costs

High development costs remain a major challenge in the lipid regulators market. The process of discovering, developing, and commercializing new lipid-lowering drugs involves extensive R&D, clinical trials, and regulatory approvals, all of which require substantial financial investment. Preclinical and clinical research phases are time-consuming and expensive, involving the recruitment of skilled professionals and maintenance of specialized facilities. Additionally, ensuring safety and efficacy through compliance with stringent regulatory frameworks adds further financial burden. These cost-related barriers particularly affect smaller pharmaceutical firms, potentially limiting innovation and delaying market entry of newer lipid-regulating products.

Key Market Trends

Rise of Biopharmaceuticals

Biopharmaceuticals are reshaping the lipid regulators market by enabling more targeted, effective treatment options. Unlike traditional chemical-based drugs, biopharmaceuticals-such as monoclonal antibodies and recombinant proteins-interact with specific biological pathways to regulate lipid metabolism. These advanced therapies offer improved safety profiles and enhanced therapeutic outcomes, particularly for patients who are unresponsive to conventional statins. The advancement of technologies like gene editing and synthetic biology is accelerating the development of biologics. While the infrastructure and expertise required for biopharmaceutical development present initial investment challenges, the long-term benefits-such as premium pricing and extended patent exclusivity-make them a lucrative segment within the lipid regulators market.

Key Market Players

• AbbVie Inc
• Amgen Inc.
• Andrx Corp
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Lipid Regulators Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lipid Regulators Market, By Type:

• Statins (Branded statins, Statin combinations, and Generic statins)
• Non-statins (Fibric-acid derivatives, Bile-acid Sequestrants, Nicotinic Acid Derivatives, and Other New Products)

Lipid Regulators Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Lipid Regulators Market.

Available Customizations:

Lipid Regulators Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lipid Regulators Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type {Statins (Branded statins, Statin combinations, and Generic statins), and Non-statins (Fibric-acid derivatives, Bile-acid Sequestrants, Nicotinic Acid Derivatives, and Other New Products)}
  • 5.2.2. By Region
  • 5.2.3. By Company (2024)
• 5.3. Market Map

6. North America Lipid Regulators Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lipid Regulators Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
  • 6.3.2. Canada Lipid Regulators Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
  • 6.3.3. Mexico Lipid Regulators Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type

7. Europe Lipid Regulators Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lipid Regulators Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
  • 7.3.2. United Kingdom Lipid Regulators Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
  • 7.3.3. Italy Lipid Regulators Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
  • 7.3.4. France Lipid Regulators Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
  • 7.3.5. Spain Lipid Regulators Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type

8. Asia-Pacific Lipid Regulators Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Lipid Regulators Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
  • 8.3.2. India Lipid Regulators Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
  • 8.3.3. Japan Lipid Regulators Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
  • 8.3.4. South Korea Lipid Regulators Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
  • 8.3.5. Australia Lipid Regulators Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type

9. South America Lipid Regulators Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lipid Regulators Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
  • 9.3.2. Argentina Lipid Regulators Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
  • 9.3.3. Colombia Lipid Regulators Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type

10. Middle East and Africa Lipid Regulators Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Lipid Regulators Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
  • 10.3.2. Saudi Arabia Lipid Regulators Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
  • 10.3.3. UAE Lipid Regulators Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Lipid Regulators Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. AbbVie Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Andrx Corp
• 15.4. AstraZeneca PLC
• 15.5. Bristol-Myers Squibb Co
• 15.6. Merck KGaA
• 15.7. Novartis AG
• 15.8. Pfizer Inc.
• 15.9. Teva Pharmaceutical Industries Ltd
• 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer